DOI: http://dx.doi.org/10.18203/2320-6012.ijrms20162923

Evaluation of serum paraoxonase level and dyslipidemia in psoriasis

Prathibha K, Aliya Nusrath, Rajeshwari A.

Abstract


Background: Psoriasis is a chronic recurrent inflammatory skin disorder that is associated with oxidative stress, altered lipid metabolism and with high risk of cardiovascular events. High density lipoprotein (HDL) bound serum paraoxonase enzyme exhibits anti-atherogenic properties. It protects against the development of coronary heart disease by preventing low density lipoprotein (LDL) oxidation. The aim of our work was to evaluate the serum paraoxonase levels and dyslipidemia in psoriasis.

Methods: Present study involved 100 participants of which 50 were diagnosed cases of psoriasis and 50 were age and sex matched healthy controls, who fulfilled inclusion criteria. Serum paraoxonase (PON), and lipid profile were estimated in cases and controls. Lipid profile was estimated by using autoanalyser EM 200 and serum paraoxonase by spectrophotometric method.

Results: Patients presented risk changes in lipid profile [(increase in triglycerides (p=0.005), low density lipoprotein cholesterol (p=0.009), very low density levels (p=0.002) and a reduction in high density lipoprotein cholesterol (p≤0.001)] which were highly significant when compared to controls. Serum paraoxonase levels was decreased in psoriasis patient compared to control which was statistically highly significant (p= 0.001).

Conclusions: Present data suggest that psoriasis patients must be considered as a group at risk for cardiovascular disease.


Keywords


PON, Psoriasis, Dyslipidemia, HDL, Cardiovascular disease

Full Text:

PDF

References


Aldona P, Anna MS, Grazyna C, Jacek CS. Lipid disturbances in psoriasis: An update. Mediators of Inflammation. 2010.

Pavithra K, Karunakaran M, Aparna P, Ragunath S. Disorders of keratinization. In Valia RG, Ameet RV. IADVL Textbook of Dermatology, vol 1. 3rd ed. Mumbai, Bhalani publishing house. 2008;1021-56.

Traub M, Marshall KMS. Psoriasis – Pathophysiology, Conventional, and alternative approaches to treatment. Alternative Medicine Review. 2007;12(4):319-30.

Balato A, Balato N, Megna M, schiattarella M, Lembo S, Ayala F. Pathogenesis of psoriasis: The role of pro – inflammatory cytokines produced by keratinocytes. DOI: 10.5772/26163.

Nijsten T, Wakkee M. Complexity of the association between psoriasis and comorbidities. Journal of Investigative Dermatology. 2009;129(7):1601-3.

Pietrzak A, Janowski K, Janowski K. Psoriasis and heart. Something new under the sun. Giornale Italiano di Dermatologia e Venereologia. 2006;141(5):457-63.

Pietrzak A, Lecewicz-Toruń B, Kądziela-Wypyska G. Changes in the digestive system in patients suffering from psoriasis. Annales Universitatis Mariae Curie-Sklodowska. Sectio D. 1998;53:187-94.

Blatter MC, James RW, Messmer S, Barja F, Pometta D. Identification of a distinct human high-density lipoprotein subspecies defined by a lipoprotein-associated protein, K-45. Identity of K-45 with paraoxonase. Eur J Biochem. 1993;211(3):871-9.

Watson AD, Berliner JA, Hama SY, La Du BN. Protective effect of high density lipoprotein associated paraoxanase. Inhibition of the biological activity of minimally oxidized low density lipoprotein. J Clin In-vest. 1995;96(6):2882-91.

Sanghera DK, Saha N, Aston CE, Kamboh MI. Genetic polymorphism of paraoxonase and the risk of coronary heart disease. Arterioscler Thromb Vasc Biol. 1997;17(6):1067-73.

Mackness B, Davies GK, Turkie W. Paraoxonase status in coronary heart disease: are activity and concentration more important than genotype? Arterioscler Thromb Vasc Biol. 2001;21(9):1451-57.

Vanizor KB, Orema A, Cimsit G, Yandi YE, Calapoglu M. Evaluation of atherogenic tendency of lipids and lipoprotein content and their relationships with oxidant and antioxidant system in patients with psoriasis. Clin Chim Acta. 2003;328(1-2):71-82.

Rocha-Pereira P, Santos-Silva A, Rebelo I, Figueiredo A, Quintanilha A, Teixeira F. Dyslipidemia and oxidative stress in mild and in severe psoriasis as a risk for cardiovascular disease. Clin Chim Acta. 2001;303(1-2):33-9.

Pietrzak A, Lecewicz-Torun B. Activity of serum lipase [EC 3.1.1.3] and diversity of serum lipid profile in psoriasis. Med Sci Moniy. 2002;8(1):CR9-CR13.

Nagane NS, Ganu JV. Lipid profile and serum paraoxonase1 activity in CRF patient’s pre and post hemodialysis. Al Ameen J Med Sci. 2011;4(1):61-8.

Menys VC, Liu Y, Durrington PN. Semiautomated method for determination of serum paraoxonase activity using paraoxon as substrate. Clinical chemistry. 2006;52(3):453-7.

Toker A, Kadi M, Yildirim AK, Aksoy H, Akcay F. Serum Lipid Profile Paraoxonase and Arylesterase activities in Psoriasis. Cell biochemistry and function. 2009;27:176-80.

Cabana GV, Rearddon CA, Feng N, Neath S, Lukens J, Getz GS. Serum paraoxonase; Effect of the apolipoprotein composition of HDL and the acute phase response.

Mackness B, Durrington PN. High density lipoprotein, its enzyme and its potential to influence lipid peroxidation. Atherosclerosis. 1995;115:243-53.

Navab M, Hama SY, Van Lanten BJ, Fonarow GC, Cardinez CJ, Castellani LW. Mildly oxidized LDL induces an increased apolipoprotein j /paraoxonase ratio. J Clin Invest. 1997;99:2005-19.

Ferretti G, Bacchetti T, Marchionni C, Caldarelli L, Curatola G. Effect of glycation of high density lipopro-teins on their physicochemical properties and on paraoxonase activity. Acta Diabetol. 2002;38:163-69.

Ferretti G, Bacchetti T, Marotti E, Curatola G. Effect of homocysteinylation on human high-density lipoproteins: a correlation with paraoxonase activity. Metabolism. 2003;52:146-51.